InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Browse the detailed record of transactions filed by Hillan Kenneth J., Director. Officer active across 2 companies, notably 23andMe Holding Co.. Cumulatively, 4 disclosures have been logged. Activity tracked since 9 February 2022. The latest transaction was disclosed on 1 June 2022 (Retenue fiscale). Regulator: SEC (Form 4). All data is openly available.
Declarations4 total
4,627 shares@ US$2.82100.0% of flowClass A Common StockSEC:0001209191-22-033526:0
12,500 shares0Common StockSEC:0001209191-22-014134:0
214,091 shares0Class A Common StockSEC:0001209191-22-008865:0
214,091 shares0Class A Common StockSEC:0001209191-22-008865
4 of 4 declarations
About Hillan Kenneth J.
Kenneth J. Hillan is the Head of Therapeutics and a Board Member at 23andMe Holding Co. and Sangamo Therapeutics, Inc. In these roles, he oversees research and development initiatives and contributes to strategic decision-making. With experience in the biopharmaceutical sector, he plays a crucial role in innovation and the development of new treatments.
